Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · KYNTRA BIO, INC. (KYNB)

Kyntra Bio cuts royalty financing cap to $65 million with $42.6 million upfront payment

Mixed Impact 4 of 5 financing Written later

Kyntra Bio amended its royalty financing agreement with NQ Project Phoebus, L.P., lowering the maximum aggregate payments from $125 million to $65 million in exchange for a $42.6 million accelerated upfront payment. The company says the amendment and the FibroGen Europe bankruptcy together reduce its future liabilities by approximately $80 million, but pro forma cash, cash equivalents, investments, and accounts receivable fall to $53.1 million from $95.7 million as of June 30, 2026.

Key points

  • Maximum aggregate payments reduced from $125 million to $65 million, a $60 million reduction in payment obligations
  • $42.6 million upfront payment brings total payments to NQ Project Phoebus to $50 million, a full return of its invested capital
  • Remaining $15 million cap to be paid from 50% of Astellas revenue for EVRENZO sales in Europe and other Astellas territories excluding Japan
  • Pro forma cash and related balances of $53.1 million as of June 30, 2026; company expects cash runway into the fourth quarter of 2027

The filing

CompanyKYNTRA BIO, INC. (KYNB)
Form8-K, current report
Filed with the SECAug 31, 2026, 5:18 PM ET
Accession number0001193125-26-377059

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 31, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.